PLSE
Pulse Biosciences, Inc.
NASDAQ · Healthcare · Medical - Instruments & Supplies · US
$53.24
−2.69%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -16.2%
- EBIT
- -15.0%
- EPS
- -9.3%
- Free cash flow
- -37.2%
- Operating cash flow
- -37.3%
Forward estimates
Based on analyst estimates
- Revenue
- +262.9%
- EBITDA
- -14.3%
- EPS
- -14.0%
Three-year CAGR
- Revenue
- -20.6%
- EBITDA
- -36.8%
- EBIT
- -36.8%
- Net income
- -35.8%
- EPS
- -17.4%
- Free cash flow
- -49.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026